| PLX:Protalix Biotherapeutics Inc | | Charting | News | Options | |||||||||||||
| ||||||||||||||
| ||||||||||||||
| ||||||||||||||
20.79% $0.58
 Markets |
 Portfolio |
| |
| |
|
| |
|
|
|
|||||||||||||||||||||||||||||
|
| ||||||||||||||||||||||||||||||
|
| Latest Story |
|
| Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026 |
|
| PR Newswire |
|
Company to host conference call and webcast at 8:00 a.m. EDT Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that it will release its financial results for the fiscal year ended December 31, 2025 and provide a business update on March 18, 2026. |
| Full Story → |
|
| Headline News |
|
| Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio(R) (pegunigalsidase alfa) |
| 6:00a ET March 9 '26 GlobeNewswire |
|
|
| Ellomay Capital Announces Changes in its Principal Shareholders and Board Composition |
| 4:32p ET March 4 '26 GlobeNewswire |
|
|
| Levi & Korsinsky Launches Fraud Investigation on Behalf of Protalix BioTherapeutics, Inc. (PLX) Shareholders |
| 1:09p ET March 2 '26 Newsfile Corp |
|
| More News → |
| ||
|
|
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
| March 18 '26. Markets Closed. | ||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||||
| Previous data from yesterday, March 17 '26. | ||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
| Historical Price Performance | ||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
|
Market data provided by 
News provided by   |
22.78% 
